RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
NCT04176380
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
The RAPA-201-RRMM study is testing a treatment called autologous T cells on adults with a type of cancer called multiple myeloma. The study is for people who have already had three different treatments but their cancer has come back.
The RAPA-201-RRMM study is testing a treatment called autologous T cells on adults with a type of cancer called multiple myeloma. The study is for people who have already had three different treatments but their cancer has come back.
Third Opinion AI Generated Synopsis
Trial Summary
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
